

## **Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)**

**June 1, 2022 – The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Wednesday 1 June 2022. The following resolutions, amongst others, were passed at the general meeting:**

### **Adoption of the income statements and balance sheets, disposal of profits, and resolution regarding discharge of liability**

The annual general meeting resolved to adopt the income statement and balance sheet and the group's income statement and balance sheet for the financial year of 2021.

The annual general meeting resolved, in accordance with the board of directors' proposal, that no dividend will be paid for the financial year of 2021.

The annual general meeting resolved to grant discharge of liability for the members of the board of directors and the managing director for the financial year of 2021.

### **Board of directors, auditors, and fees**

In accordance with the nomination committee's proposal, the annual general meeting resolved that the board of directors shall consist of six ordinary members without deputies. Furthermore, the annual general meeting resolved to re-elect the board members Wenche Rolfsen (chairman), Marlene Forsell, Uli Hacksell and Lennart Hansson and to elect Karin Bernadotte af Wisborg and Anna-Kaija Grönblad as ordinary board members for the time until the end of the next annual general meeting. The annual general meeting further resolved on the re-election of the auditing company PricewaterhouseCoopers (PwC) as the company's auditor, with the authorized public accountant Magnus Lagerberg as the auditor in charge.

The annual general meeting resolved, in accordance with the nomination committee's proposal, that the fees for the board of directors for the time until the end of the next annual general meeting shall amount to SEK 500,000 for the chairman of the board of directors and SEK 235,000 for each ordinary member of the board of directors. Fees to the company's auditor for the same period shall be paid in accordance with approved invoices.

### **Resolution regarding an authorization for the board of directors to increase the share capital**

The annual general meeting resolved, in accordance with the board of directors' proposal, on an authorization for the board of directors to – for the period up to the next annual general meeting and at one or more occasions – resolve upon issuance of new shares, warrants and/or convertible debentures. Payment may be made in cash, in kind, through set-off of claims or otherwise be conditional. The company's share capital may by support of the authorization be increased by an amount corresponding to 10 per cent of the share capital and number of shares in the company as of on the date the board of directors make use of the authorization. Deviation from the shareholders' preferential rights shall be allowed in situations where a directed issue is deemed more appropriate for the company due to timing, commercial or similar reasons, and in order to enable acquisitions.

### **Resolution on the implementation of a long-term incentive programme in the form of employee stock options**

The annual general meeting resolved, in accordance with the board of directors' proposal, on the implementation of a long term incentive programme by way of granting employee stock options to senior executives and other key persons of the group giving right to acquire new shares in the company, including the issue of warrants entitling to subscription of new shares in the company in order to enable delivery of shares under the programme and to cover potential cash flow effects from social security costs arising from the programme. The employee stock options and the warrants, respectively, shall be subject to the terms and conditions presented in the board of directors' complete proposal.

**The required majority was not obtained to implement a long-term incentive programme for board members**

As a result of some investors voting against Linc AB's proposal, the required majority was not obtained to implement a long-term incentive programme for board members.

**For more information:**

Johan Giléus, Acting CEO

Tel: +46 8 122 038 50

E-mail: [johan.gileus@indexpharma.com](mailto:johan.gileus@indexpharma.com)

**Publication**

The information was submitted for publication through the agency of the contact person set out above at 17:30 CET on 1 June, 2022.

**InDex Pharmaceuticals in brief**

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's foremost asset is the drug candidate cobitolimod, which is being evaluated in the phase III study CONCLUDE for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB with e-mail [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se) and phone number +46 8 121 576 90 is the company's Certified Adviser. For more information, please visit [www.indexpharma.com](http://www.indexpharma.com)